Friday 6 November 2026 Export TRLV’s income statement to Excel — free account

Trulieve Cannabis Corp.

TRLV Healthcare Drug Manufacturers Specialty & Generic

Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.

Revenue: −20.1%
EPS: −2,391.1%
Free cash flow: +24.5%
Total debt: −37.0%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

11.07 0.53 −4.57%

Follow TRLV

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −5.6×
Dividend yield: —
F-score: 6/9
Altman Z: 0.98
Beneish M: −2.99
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 14.66

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	3	—	—	—	—	—

Insider Ownership 15.72%

Capital & Financial Ratios $m

Size

Market Cap 2,100.00

Revenue ttm 1,081.07

Net income ttm (446.60)

Free cash flow ttm 242.48

Net debt Q 19.62

Valuation

P/E 0.00

Forward P/E (5.64)

Price / sales 1.98

Forward P/S Powerpack

Price / FCF 11.84

Price / book 2.77

Financial health

Current ratio Q 5.52

Debt / equity Q 0.00

Interest coverage Q 0.00

Growth

Revenue growth Q −20.12%

Operating income growth Q −803.11%

EPS, this year −217.38%

EPS, next year A +119.32%

Revenue, next year A −14.66%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 81.51%

10-year low 10-year high

P/B against its own 10 years 97.53%

10-year low 10-year high

EV/Sales against its own 10 years 73.46%

10-year low 10-year high

EV/FCF against its own 10 years 64.40%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	208	300	256	—
Receivables	7	18	19	—
Inventory	213	231	242	191
Other	24	26	25	2
	477	605	563	563

	2023	2024	2025	Q'26
Payables	83	94	83	68
ST’ Debt	—	—	—	—
Other	6	8	3	—
	115	138	127	102

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.76%	(1.02%)
Cash Flow	—	22.32%	127.74%
Earnings	—	0.00%	0.00%
Book Value	—	—	(15.99%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.06 Actual 0.11

0.05 0.07 0.08 0.10 0.12

Q2 FY26 Beat +0.05

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY26	0.06	0.11	Beat by 0.05
Q3 FY26	0.09	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	(2.10)	—	—	—
’25	(0.16)	(0.08)	(0.15)	(0.23)	(0.58)
’24	(0.13)	(0.06)	(0.33)	(0.32)	(0.79)
’23	(0.35)	(2.15)	(0.14)	(0.18)	(2.28)
’22	(0.17)	(0.13)	(0.61)	(0.43)	(1.34)
’21	0.24	0.31	0.14	(0.56)	0.12

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	287	271	230	—	—
’25	298	302	288	293	1,181
’24	298	303	284	301	1,186
’23	285	282	275	287	1,129
’22	318	314	295	291	1,218
’21	194	215	224	299	932

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	56	53	74	—	—
’25	51	86	76	59	273
’24	139	71	30	31	271
’23	0	(23)	93	131	202
’22	45	(55)	(22)	55	23
’21	60	(10)	26	(62)	13

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	42	32	74	—	—
’25	30	70	60	52	212
’24	119	39	(15)	(19)	124
’23	(19)	(29)	87	108	151
’22	(13)	(109)	(61)	23	(161)
’21	7	(82)	(53)	(104)	(233)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	522	932	1,218	1,129	1,186	1,181	1,081		+17.8%	1,008	936	919	(8.0%)
	Gross margin, %	—	—	—	—	74.09	60.80	56.57	52.13	60.32	60.21	60.64		(13.9) pt	Powerpack Trulieve Cannabis Corp.’s next three years, line by line Analysts expect revenue to shrink 8.0% a year to 2028 — slower than the 17.8% of the last 5 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	—	157	176	(19)	(285)	43	91	(328)		(10.3%)
	EBT margin, %	—	—	—	—	30.19	18.91	(1.58)	(25.20)	3.60	7.74	(30.36)		(22.4) pt
	Net income	—	—	—	—	63	17	(253)	(533)	(161)	(122)	(447)		n/m
Per share, $
Per share, $	Revenue	—	—	—	—	4.59	6.69	6.48	5.98	6.24	6.17	5.60		+6.1%
	Earnings	—	—	—	—	0.55	0.13	(1.34)	(2.28)	(0.79)	(0.58)	(2.47)		n/m
	Cash flow	—	—	—	—	0.88	0.09	0.12	1.07	1.43	1.43	1.26		+10.2%
	Capex	—	—	—	—	(1.25)	(1.76)	(0.98)	(0.27)	(0.78)	(0.32)	0.00		(24.0%)
	Free cash flow	—	—	—	—	(0.37)	(1.67)	(0.86)	0.80	0.65	1.11	1.26		n/m
	Book value	—	—	—	—	0.00	15.41	10.25	7.45	6.57	5.97	4.00		n/m
	Shares, m	—	—	—	—	114	139	188	189	190	191	192		+11.0%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	207.75	207.75	0.00	0.00	0.00	0.00	0.00		69.2
	P/S	—	—	—	—	0.00	3.89	1.12	0.86	0.83	1.41	1.98		1.4
	P/B	—	—	—	—	0.00	1.69	0.71	0.69	0.79	1.45	2.77		0.9
	EV/Sales	—	—	—	—	0.00	4.21	1.53	1.16	1.04	1.44	1.99		1.6
	EV/FCF	—	—	—	—	0.00	(16.88)	(11.70)	8.90	10.25	8.15	11.95		(0.2)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	100	13	23	202	271	273	242		+22.3%
	Capex	—	—	—	—	(142)	(246)	(184)	(51)	(148)	(61)	(58)		(15.7%)
	Free cash flow	—	—	—	—	(42)	(233)	(161)	151	124	212	242		n/m
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	355	383	362	466	436	461		+5.2%
	Net debt	—	—	—	—	—	302	492	333	244	36	20		(41.1%)
	Shareholders’ equity	—	—	—	—	—	2,147	1,928	1,409	1,249	1,143	772		(14.6%)
Returns, %
Returns, %	ROA	—	—	—	—	0.00	0.00	(7.22)	(17.19)	(5.54)	(4.18)	(17.61)		(4.2) pt
	ROIC	—	—	—	—	0.00	5.21	1.30	(7.95)	4.09	7.61	0.00		+7.6 pt
	ROE	—	—	—	—	0.00	0.00	(12.08)	(31.58)	(11.67)	(9.73)	(45.52)		(9.7) pt
People
People	Employees	—	—	—	—	—	—	7,600	5,400	6,000	5,000	—		(13.0%)
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.16	0.21	0.20	0.24	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RGC Regencell Bioscience Holdings Limited	$2.6B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.5B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
XERS Xeris Biopharma Holdings, Inc.	$2.4B	— (loss-making)	— (loss-making)	+44.16% (above 0%: growing)	+1,478.95% (above 0%: growing)	+93.18% (above 0%: growing)	88.41%	15.78%	Compare
PRGO Perrigo Company plc	$2.2B	— (loss-making)	— (loss-making)	−5.24% (below 0%: shrinking)	n/m	+138.48% (above 0%: growing)	32.45%	2.34%	Compare
TRLV Trulieve Cannabis Corp.	$2.1B	— (loss-making)	— (loss-making)	−20.12% (below 0%: shrinking)	n/m	+24.49% (above 0%: growing)	64.30%	0.00%
PBH Prestige Consumer Healthcare Inc.	$2.1B	13.7×	11.7×	+22.69% (above 0%: growing)	−38.37% (below 0%: shrinking)	−38.18% (below 0%: shrinking)	51.30%	24.00%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.0B	— (loss-making)	— (loss-making)	+13.11% (above 0%: growing)	+150.00% (above 0%: growing)	−18.69% (below 0%: shrinking)	99.13%	29.58%	Compare
ALVO Alvotech	$1.8B	— (loss-making)	111×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.6B	13.3×	14.3×	+27.64% (above 0%: growing)	+29.41% (above 0%: growing)	+85.49% (above 0%: growing)	61.64%	18.01%	Compare
Median of peers	$2.1B	—	14.3×	+27.64%	+89.71%	+71.32%	58.69%	15.78%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 25 June 2026

Ownership

Directors and executive officers, together 14.00%

Kim Rivers 10.33%

Jason Pernell 2.62%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement